Biond Biologics is pleased to participate in the Great Bay Area ADC & Antibody Forum 2026, bringing together leaders from across the global antibody therapeutics and biotechnology community to discuss emerging technologies and the next generation of innovative medicines.
At the conference, Biond is presenting BND-67, our first-in-class antibody-based therapy designed to prevent pathological CD28 shedding in cancer patients. By preserving CD28 signaling, BND-67 is designed to enhance effector T-cell activity while reducing regulatory T-cell-mediated immune suppression, offering a differentiated approach to restoring anti-tumor immunity. BND-67 entered Phase 1 clinical development in Q2 2026, with development focused on selected tumor types responsive to immune-based therapies
